Citadel Advisors
PRCT icon

Citadel Advisors’s Procept Biorobotics PRCT Stock Holding History

Citadel Advisors’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$538K Buy
21,500
+1,900
+10% +$53.5K ﹤0.01% 9124
2025
Q4 		$617K Sell
19,600
-25,600
-57% -$849K ﹤0.01% 8527
2025
Q3 		$1.61M Buy
45,200
+19,600
+77% +$895K ﹤0.01% 6506
2025
Q2 		$1.47M Sell
25,600
-5,900
-19% -$334K ﹤0.01% 6298
2025
Q1 		$1.84M Sell
31,500
-1,300
-4% -$88.8K ﹤0.01% 5696
2024
Q4 		$2.64M Buy
32,800
+6,000
+22% +$513K ﹤0.01% 5066
2024
Q3 		$2.15M Sell
26,800
-9,600
-26% -$682K ﹤0.01% 5402
2024
Q2 		$2.22M Sell
36,400
-16,800
-32% -$999K ﹤0.01% 5116
2024
Q1 		$2.63M Sell
53,200
-4,400
-8% -$209K ﹤0.01% 5011
2023
Q4 		$2.41M Buy
57,600
+39,100
+211% +$1.33M ﹤0.01% 5040
2023
Q3 		$607K Sell
18,500
-48,800
-73% -$1.66M ﹤0.01% 7635
2023
Q2 		$2.38M Buy
67,300
+2,200
+3% +$72.7K ﹤0.01% 4851
2023
Q1 		$1.85M Buy
65,100
+53,100
+443% +$1.87M ﹤0.01% 5539
2022
Q4 		$498K Sell
12,000
-1,400
-10% -$60.1K ﹤0.01% 8242
2022
Q3 		$556K Buy
+13,400
New +$534K ﹤0.01% 8226

Other funds holding PRCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors's PRCT Position: Q1 2026 in Review

Citadel Advisors sold out of Procept Biorobotics (PRCT) in Q1 2026, closing a stake of 91,061 shares — an estimated $2.57M sold.

Citadel Advisors first reported a position in PRCT in Q3 2021 and held it in 18 quarters. The position peaked at $36.6M in Q3 2023. 256 funds tracked by Wall St. Rank hold PRCT as of Q1 2026.

  • Citadel Advisors reported no remaining Procept Biorobotics position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 91,061 Procept Biorobotics shares in Q1 2026, an estimated $2.57M.
  • Citadel Advisors first reported a position in Procept Biorobotics in Q3 2021 and held it in 18 quarters.
  • Citadel Advisors's Procept Biorobotics position peaked at $36.6M in Q3 2023.
  • 256 funds tracked by Wall St. Rank held Procept Biorobotics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.